Marc A. Dall'Era, M.D.
Chair, Department of Urologic Surgery
Professor
To see if Marc A. Dall'Era is accepting new patients, or for assistance finding a UC Davis doctor, please call 800-2-UCDAVIS (800-282-3284).
Department
Locations and Contact
Phone: 916-734-2222
UC Davis Comprehensive Cancer Center
UC Davis Comprehensive Cancer Center
2279 45th Street
Sacramento, CA 95817
Phone: 916-734-5959
UC Davis Medical Group - Point West
UC Davis Medical Group - Point West
1535 River Park Drive
Sacramento, CA 95815
Additional Numbers
Physician Referrals
Philosophy of Care
Throughout his career, Dr. Dall'Era has remained committed to providing his patients with the highest quality of care. He believes in taking a patient-centered approach, which means that he listens carefully to his patients' concerns, values their input, and works with them to develop a personalized treatment plan that meets their unique needs.
For Dr. Dall'Era, urologic surgery is not just about fixing problems or performing procedures; it's about improving patients' overall quality of life. He understands that many urological conditions can be stressful and embarrassing, and he works hard to create a safe and welcoming environment where his patients feel comfortable discussing their symptoms and concerns.
Clinical Interests
Dr. Dall’Era specializes in the management of malignant disease of the urinary tract. The specialty care Dr. Dall’Era offers includes:
- Multi-disciplinary and comprehensive care of patients with urologic malignancy
- Personalized prostate cancer care based on disease characteristics and patient preferences
- Transperineal prostate biopsy utilizing high-resolution ultrasound for better and safer prostate cancer diagnosis and characterization
- High intensity focused ultrasound (HIFU) for prostate cancer treatment
- Multi-parametric MRI/US fusion targeted prostate biopsy
- Minimally invasive and robotic surgery of the kidney and prostate including prostatectomy partial and radical nephrectomy
- Advanced genomics testing of urologic cancers
Research/Academic Interests
Dr. Dall'Era's research interests include active surveillance for prostate cancer, including utilization of mp-MRI and biomarker discovery and validation. He is a principal investigator on several clinical trials including for men with high-risk prostate cancer and for focal therapy of early-stage disease.
Division
Urology
Center/Program Affiliation
Undergraduate School
B.S., UC Davis, Davis CA 1995
Medical School
M.D., UC Davis, Davis CA 2000
Internship
General Surgery, University of Washington, Seattle WA 2000-2001
Residency
Urology, University of Washington, Seattle WA 2001-2005
Fellowship
Oncology, UC San Francisco, San Francisco CA 2006-2008
UC Davis Health Diamond Doc Award, FY 2025 Q2,
UC Davis Health Diamond Doc Award, FY 2024 Q1-Q4,
UC Davis Health Diamond Doc Award, FY 2023 Q1,
Societe Internationale D'Urologie Outstanding Webcast Award, 2020
UC Davis Health Clinician Health and Wellbeing Excellence Award, 2020
UC Davis Comprehensive Cancer Center Clinical Trials Top Accrual Award, 2018
Access Dr. Dall'Era's bibliography here.
Qu H, Xu P, Yang JC, Wei F, Zhao J, Wang L, Corey E, Mitsiades N, Lam K, Iczkowski KA, Li Y, Gao AC, Dall’Era M, Liu C. Glutamate Ionotropic Kainate Receptors as Therapeutic Targets in Enzalutamide-Resistant and Neuroendocrine Prostate Cancer. Int J Mol Sci. 2026 Jul 2;27(13):5945.
Pan CX,Mossanen M, Ellis JL, Ma AH, Yang C, Farrukh H, Jiao Y, Bhardwaj U, Lee JS, Lare PN, Hynes C, Lin TY, Li Y, Preston MA, Kibel A, Dall’Era M, Lam KS. Phase I First-in-Human Dose-Escalation Trial of a Bladder Cancer-Specific Nanoparticle in Non-Muscle-Invasive Bladder Cancer. Nanomedicine (Lond). 2026 Jul 8:1-7. Online ahead of print.
Narayan A, Leibrandt RC, Lee JS, Dall’Era MA, Whitson JM, Chandrasekar T, Braun A, Mossanen M, Li H, Lara PN Jr, Lam KS, Pan CX, Parikh M. A Phase I Trial of PLZ4-Coated Paclitaxel-Loaded Micelles in Patients with Refractory Non-Muscle-Invasive Bladder Cancer. Nanomedicine (Lond). 2026 Jun 1:1-6. Online ahead of print.
Correa Gonzalez B, Karthikeyan A, Moore LA, Bhaumik A, Sandoval E, Hardy M, McPherson JD, Li H, Parikh M, Dall’Era M, Gao AC, Lombard AP. Characterizing Response to PARP Inhibitor Treatment Combinations in Advanced Prostate Cancer. Biomedicines. 2026 Apr 22;12(5):949.
Schaaf ZA, Ning S, Leslie AR, Sharifi M, Gao RY, Maine LP, Leslie KD, Shen Y, Lombard AP, Lou W, Li PK, Liu C, Dall’Era M, Gao, AC. Targeting NDUFS4 Disrupts Oxidative Phosphorylation and Induces Ferroptosis in Olaparib-Resistant Prostate Cancer. Mol Cancer Ther. 2026 Apr 9. doi 10.1158/1535-7163.MCT-25-1157. Online ahead of print.
Yang Y, Zhang X, Venkadakrishnan VB, Zou H, Zheng X, Guo S, Chen CZ, Borowsky AD, Corey E, Evans RM, Gao AC, Dall’Era MA, Zoubeidi A, Lara PN, Kung HJ, Beltran H, Chen HW. Targeting Wnt/β-Catenin and Circadian Regulator Restores PRC2/EZH2 Controlled Chromatin Bivalency and Suppresses Cell State Diversity. J Clin Invest. 2026 Mar 17:e200260. doi: 10.1172/JCI200260. Online ahead of print.
Bec J, Zhou X, Tipirneni, Chen S, Qi J, Iczkowski KA, Dall’Era M, Marcu L. Label-free Fluorescence Lifetime Imaging for Rapid Discrimination of High-Grade Prostate Cancer in Fresh Biopsy Cores: A Feasibility Study. J Biomed Opt. 2026 Mar;31(3):036001.
Xu P, Qu H, Yang JC, Wei F, Zhao J, Tang M, Wang L, Nip C, Li H, Gao AC, Lam K, Dall’Era M, Li Y, Liu C. Dynamic Reprogramming of Immune-Related Signaling During Progression to Enzalutamide Resistance in Prostate Cancer. Cancers (Basel). 2025 Sep 30;17(19):3187.
Leslie AR, Ning S, Sharifi M, Schaaf ZA, Maine JP, Lou W, Leslie KD, Liu C, Xu H, Lombard AP, Chen HW, Parikh M, Dall’Era M, Gao AC. IGFBP3-SphK1/S1P Signaling Axis Drives Enzalutamide Resistance in Advanced Prostate Cancer. Mol Cancer Ther. 2025 Dec 5:10.1158/1535-7163.MCT-25-0644.
Hairston DWS, Sridharan-Weaver S, Gandhi A, Batra N, Durbin-Johnson BP, Dall’Era MA, Ghosh PM. The Oncometabolite 2-Hydroxyglutarate is Upregulated in Post-Prostatectomy PSA Recurrence of Prostate Cancer: A Metabolomic Analysis. Molecules. 2025 Aug 8;30(16):3316.